Other guidelines, such as National Comprehensive Cancer Network [12], have made no specific distinction between different PALB2 mutations but do raise a general caution around the interpretation of testing for mutations in PALB2 and other “moderate penetrance” breast cancer predisposition genes, especially as part of panel tests. The gene discussed is PALB2; the disease is breast carcinoma.